<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nontyphoidal &lt;i&gt;Salmonella &lt;/i&gt;bacteremia and extraintestinal infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nontyphoidal <i>Salmonella </i>bacteremia and extraintestinal infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nontyphoidal <i>Salmonella </i>bacteremia and extraintestinal infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth L Hohmann, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Salmonellae are motile gram-negative bacilli that infect or colonize a broad range of mammalian hosts. They cause a number of clinical infections in humans, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroenteritis</p><p class="bulletIndent1"><span class="glyph">●</span>Enteric fever (systemic illness with fever and abdominal symptoms)</p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia and endovascular infection</p><p class="bulletIndent1"><span class="glyph">●</span>Focal metastatic infections such as osteomyelitis or abscess</p><p class="bulletIndent1"><span class="glyph">●</span>An asymptomatic chronic carrier state</p><p></p><p>Enteric fever is caused by <em>Salmonella typhi</em> and <em>Salmonella paratyphi</em>. The microbiology, epidemiology, clinical features, and treatment of these infections are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2712.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Treatment and prevention"</a>.)</p><p>Other <em>Salmonella</em> serotypes are collectively known as nontyphoidal salmonellae. Issues related to the epidemiology, clinical manifestations, diagnosis, and treatment of nontyphoidal <em>Salmonella</em> bacteremia and other invasive infections are reviewed here.</p><p>Issues related to nontyphoidal <em>Salmonella</em> gastrointestinal infection and asymptomatic carriage are discussed separately, as are general issues related to the microbiology, epidemiology, and pathogenesis of nontyphoidal salmonellae. (See  <a class="medical medical_review" href="/z/d/html/2697.html" rel="external">"Nontyphoidal Salmonella: Gastrointestinal infection and asymptomatic carriage"</a> and  <a class="medical medical_review" href="/z/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology"</a> and  <a class="medical medical_review" href="/z/d/html/2700.html" rel="external">"Pathogenesis of Salmonella gastroenteritis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Invasive infections due to nontyphoidal <em>Salmonella</em> occur globally; the burden varies by geographic location. Approximately 65 percent of cases worldwide occur among children &lt;5 years of age.</p><p>Approximately 1 percent of enteric infections with nontyphoidal <em>Salmonella</em> result in bacteremia; however, the true rate of bacteremia is unknown since many enteric infections are not diagnosed microbiologically. In a systematic review that extrapolated the global incidence of invasive nontyphoidal <em>Salmonella</em> infections based on 35 studies, there were an estimated 535,000 cases in 2017 (7.5 cases per 100,000 people worldwide) [<a href="#rid1">1</a>]. The greatest burden was in sub-Saharan Africa, which accounted for 79 percent of all cases globally [<a href="#rid1">1</a>] and where nontyphoidal <em>Salmonella</em> bacteremia is a leading cause of bacteremia in adults and children [<a href="#rid2">2-7</a>]. According to one systematic review, nontyphoidal <em>Salmonella</em> causes 8 to 39 percent of cases of community-acquired bacteremia in sub-Saharan Africa [<a href="#rid8">8</a>]. In these areas, nontyphoidal <em>Salmonella</em> bacteremia may occur in epidemic waves (more common during and just after rainy seasons) and mortality may be very high. </p><p class="headingAnchor" id="H4"><span class="h2">Host risk factors</span><span class="headingEndMark"> — </span>Patients at increased risk for nontyphoidal <em>Salmonell</em>a bacteremia or associated complications include  (<a class="graphic graphic_table graphicRef143569" href="/z/d/graphic/143569.html" rel="external">table 1</a>) [<a href="#rid9">9-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients &lt;12 months or &gt;50 years of age</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients in the following categories:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with HIV infection, especially if poorly controlled</p><p class="bulletIndent2"><span class="glyph">•</span>Organ transplant recipients</p><p class="bulletIndent2"><span class="glyph">•</span>Patients receiving corticosteroids or other immunosuppressive agents</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with cancer or lymphoproliferative disease with current or recent chemotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with sickle cell disease or other hemoglobinopathies</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with disorders of the reticuloendothelial system, including cirrhosis and chronic granulomatous disease</p><p class="bulletIndent2"><span class="glyph">•</span>Children with severe malarial anemia and malnutrition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with atherosclerosis or prosthetic heart valves</p><p></p><p>Alteration of the gastrointestinal tract (eg, by suppression of gastric acid, malnutrition, recent antibiotic use, or rotavirus infection) also predisposes patients to progression from enteric to systemic salmonellosis [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/2700.html" rel="external">"Pathogenesis of Salmonella gastroenteritis"</a>.)</p><p>The importance of predisposing host risk factors was illustrated in a series of 55 Malaysian adults with nontyphoidal <em>Salmonella</em> bacteremia, in which over 90 percent of patients had an underlying medical illness; 65 percent were immunocompromised (most commonly due to HIV infection or malignancy) [<a href="#rid2">2</a>]. In a 2017 systematic review of global cases of invasive nontyphoidal <em>Salmonella</em>, 8 percent of cases were associated with HIV infection [<a href="#rid1">1</a>].</p><p>In sub-Saharan Africa, nontyphoidal <em>Salmonella</em> bacteremia most commonly occurs in patients with HIV infection, infants, and young children with severe malarial anemia and malnutrition [<a href="#rid8">8</a>]. The association with malaria may be related to increased intestinal permeability and bacterial translocation in the setting of malaria infection [<a href="#rid14">14-16</a>]. Relapsing bacteremia and higher mortality are observed in the setting of concurrent HIV infection.</p><p>However, among children with nontyphoidal bacteremia in resource-abundant</p><p>settings, most have associated gastroenteritis, have no underlying comorbid illness, and recover uneventfully [<a href="#rid13">13,17,18</a>]. In a series of 144 pediatric cases of nontyphoidal <em>Salmonella</em> bacteremia in Pittsburgh in the United States (median age 10.5 months), 82 percent of patients were previously healthy [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H1318374024"><span class="h2">Risk by serotype</span><span class="headingEndMark"> — </span><em>Salmonella enteritidis </em>and <em>S. typhimurium </em>are the most commonly isolated nontyphoidal <em>Salmonella</em> serotypes overall and the most common causes of invasive infection. </p><p>Other serotypes have increased predisposition for invasive disease [<a href="#rid19">19</a>]; these include <em>Salmonella enterica </em>serotypes Dublin, Choleraesuis, Virchow, Infantis, Newport, and Heidelberg [<a href="#rid20">20-22</a>]. In addition, antibiotic-resistant strains of <em>S. typhimurium</em> are associated with a two- to threefold increase in the risk of bacteremia [<a href="#rid23">23,24</a>]. </p><p>The microbiologic features of nontyphoidal <em>Salmonella </em>are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H2503918373"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Nontyphoidal <em>Salmonella</em> are transmitted by the fecal-oral route; this includes transmission within households or between close contacts, outbreaks related to contaminated food and water, and transmission to humans from farm or pet animals. Eggs are a prime source for transmission of <em>S. enteritidis</em>; <em>S. typhimurium </em>has a broader range of food transmission sources.</p><p>Environmental reservoirs and host ranges of invasive strains remain poorly understood [<a href="#rid19">19</a>].</p><p>This issue is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology", section on 'Modes of transmission'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Bacteremia and other forms of extraintestinal infection are serious complications of <em>Salmonella</em> gastroenteritis. (See  <a class="medical medical_review" href="/z/d/html/2697.html" rel="external">"Nontyphoidal Salmonella: Gastrointestinal infection and asymptomatic carriage"</a>.)</p><p class="headingAnchor" id="H2806657029"><span class="h2">Bacteremia</span><span class="headingEndMark"> — </span>The clinical manifestations of nontyphoidal <em>Salmonella</em> bacteremia are nonspecific and may range from fever to sepsis.</p><p>In adults, the clinical presentation is variable and depends upon the <em>Salmonella</em> serotype as well as the host immune status and underlying comorbidities. "Occult" or "primary" bacteremia (defined as bacteremia not associated with an acute or recent episode of gastroenteritis) should raise clinical concern for an underlying immune defect or recrudescent infection from prior seeding of a vascular, osseous, or visceral focus. In immunocompromised hosts, even minimally symptomatic gastrointestinal illness can lead to deep infection.</p><p>In children, bacteremia is associated with gastrointestinal symptoms in 70 to 80 percent of cases [<a href="#rid17">17,25</a>]. In addition, respiratory symptoms occur among some children; in one case series including 229 children with invasive salmonellosis in Thailand, respiratory symptoms were observed in approximately 25 percent of patients [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H7"><span class="h2">Extraintestinal infection</span><span class="headingEndMark"> — </span>Nontyphoidal <em>Salmonella</em> bacteremia can progress to development of infection at any site. The most clinically important forms are endovascular infection and central nervous system infection, since definitive debridement of these sites is not feasible in most cases. Other forms include endocarditis, musculoskeletal infection, visceral infection (involvement of the spleen, liver, heart, lung, or pleura), and urinary tract involvement [<a href="#rid27">27</a>].</p><p>Organisms are most commonly isolated from stool and blood, followed by urine. Positive urine cultures may occur as a result of hematogenous seeding in the setting of immune compromise, underlying urologic abnormality, or may reflect ascending spread of infection from the perineum to the urinary tract [<a href="#rid28">28,29</a>].</p><p>Suppurative secondary foci are more common in immunocompromised patients and patients &lt;12 months or &gt;50 years of age.</p><p class="headingAnchor" id="H8"><span class="h3">Endovascular infection</span><span class="headingEndMark"> — </span>Endovascular infection is an uncommon but serious complication of nontyphoidal <em>Salmonella </em>bacteremia. The organisms have a propensity to home to existing atherosclerotic sites of large vessels in older adults. In one study from Taiwan, endovascular infection was linked to atherosclerosis in the absence of other clinical features or immunodeficiencies [<a href="#rid30">30</a>]. In small retrospective studies of adults &gt;50 years of age with nontyphoidal <em>Salmonella </em>bacteremia, 7 to 10 percent of patients had endovascular infection, typically at the site of pre-existing vascular disease [<a href="#rid31">31-33</a>]. (See  <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">"Overview of infected (mycotic) arterial aneurysm"</a>.)</p><p>The abdominal aorta (especially infrarenal aorta) is the most frequent site of vascular infection. Other sites of involvement include the thoracic aorta and other central arterial sites [<a href="#rid34">34</a>]. Clinical manifestations of endovascular infection include subacute fever, abdominal pain, and back pain. In addition, patients with endovascular infection may present with relapsing or prolonged <em>Salmonella</em> bacteremia. Retrospective studies from Taiwan suggest that rapid "time to positivity" on automated blood culture systems (&lt;10 hours) may portend a poor prognosis [<a href="#rid35">35-37</a>].</p><p class="headingAnchor" id="H1090129740"><span class="h3">Endocarditis</span><span class="headingEndMark"> — </span>Endocarditis is a relatively rare complication of nontyphoidal <em>Salmonella </em>bacteremia; it usually occurs in patients with underlying valve disease or prosthetic valves [<a href="#rid38">38,39</a>]. </p><p>Clinical manifestations of endocarditis are described separately. (See  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1185640568"><span class="h3">Musculoskeletal infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteomyelitis</strong> – Salmonellae may seed and persist within osseous abnormalities. <em>Salmonella</em> osteomyelitis occurs more commonly in children (especially those with hemoglobinopathies) and typically involves the epiphyses of long bones [<a href="#rid40">40</a>]; in adults, the axial skeleton is more typically involved [<a href="#rid41">41,42</a>]. Numerous case reports describe <em>Salmonella</em> osteomyelitis mimicking malignancy, highlighting the need for operative cultures in unusual cases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Septic arthritis</strong> – Septic arthritis may occur in native or prosthetic joints [<a href="#rid43">43</a>]. <em>Salmonella</em> musculoskeletal infection may be complicated and difficult to eradicate, particularly in the setting of orthopedic prostheses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive arthritis</strong> – Postinfectious reactive arthritis can occur after salmonellosis (as well as after <em>Campylobacter</em>, <em>Shigella</em>, and <em>Yersinia</em> gastrointestinal infection); the incidence and relative risk of each varies significantly across studies [<a href="#rid44">44,45</a>].</p><p></p><p class="headingAnchor" id="H2173059073"><span class="h3">Visceral infection</span><span class="headingEndMark"> — </span>Deep infection of virtually every body site has been reported due to bacteremic seeding, local extension, or failed clearance of organisms within the lymphatic and reticuloendothelial system, including the lymph nodes, liver, and spleen. Other described sites of involvement include the pleural space, neck, ovaries, epidural sites, and many others.</p><p>These complications are more likely in patients with immune defects or anatomical abnormalities but may occur in healthy individuals without predisposing conditions. </p><p class="headingAnchor" id="H1223552406"><span class="h3">Central nervous system infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningitis</strong> – <em>Salmonella</em> meningitis is a rare complication that typically occurs in neonates and children ≤12 months of age; for this reason, any form of nontyphoidal salmonellosis in infants should prompt immediate and attentive management [<a href="#rid46">46,47</a>]. Manifestations include fever and lethargy; complications include hydrocephalus and ventriculitis [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent1">In settings with high HIV prevalence, nontyphoidal <em>Salmonella </em>meningitis has also been described in adults. In one review of 278 cases of nontyphoidal <em>Salmonella </em>meningitis in South Africa, there were bimodal peaks at &lt;5 and &gt;15 years of age; 46 percent of patients had HIV infection [<a href="#rid49">49</a>]. Headache and signs of meningeal irritation are more common among adults. </p><p></p><p class="bulletIndent1">Mortality is high (65 percent among patients &gt;15 years old in the large series above), and survivors may not have complete neurological recovery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain abscess</strong> – <em>Salmonella</em> brain abscess may occur as a complication of meningitis or rarely after neurosurgical procedures [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H184034403"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>Among immunocompromised patients, if bacteremia occurs at an immunological nadir, infection may become established within the reticuloendothelial system. Relapse may occur even after an asymptomatic interval and in the absence of a known focus of infection (such as osteomyelitis or an abnormal biliary or urinary tract) [<a href="#rid51">51</a>]. </p><p>The risk of relapse varies by host characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>In one United States study including 82 patients with malignancy (of whom 55 had hematologic malignancy) and nontyphoidal <em>Salmonella</em> infection, relapse occurred in 6 percent of cases [<a href="#rid52">52</a>]. All relapses occurred in patients treated with less than 10 days of antibacterial therapy; mortality at 30 days was 8 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a United States study including 51 otherwise healthy children with nontyphoidal bacteremia, there was no difference in outcome between those treated with a short duration of antibiotic therapy (&lt;7 days; median 4 days) versus a longer duration (&gt;7 days; median 9 days) [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H793648696"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H289486079"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>Nontyphoidal<em> Salmonella </em>bacteremia should be suspected in patients with gastrointestinal symptoms (recent or current) and systemic febrile illness in the setting of risk factors outlined in the table  (<a class="graphic graphic_table graphicRef143569" href="/z/d/graphic/143569.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1436862358"><span class="h2">Obtaining cultures</span><span class="headingEndMark"> — </span>The diagnosis of nontyphoidal <em>Salmonella</em> bacteremia is established by blood culture. Nontyphoidal <em>Salmonella</em> grow readily in aerobic and anaerobic blood culture bottles. (See  <a class="medical medical_review" href="/z/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology", section on 'Microbiology'</a>.)</p><p>Blood cultures should be obtained in patients with clinical suspicion for nontyphoidal <em>Salmonella</em> bacteremia as outlined above (see <a class="local">'Clinical suspicion'</a> above). Isolation of <em>Salmonella</em> from urine culture should also prompt collection of blood cultures. </p><p>For patients with imaging or other findings suggestive of a mycotic aneurysm who are already receiving systemic antibiotics (which may reduce the yield of blood cultures), stool culture may be diagnostically useful. </p><p class="headingAnchor" id="H3129721895"><span class="h2">Evaluation for extraintestinal complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – Patients with nontyphoidal <em>Salmonella</em> bacteremia should have a careful physical examination for possible extraintestinal metastatic foci of infection. A pulsatile abdominal mass should raise concern for aortic aneurysm. A cardiac murmur should raise concern for endocarditis. Bone or joint pain should prompt consideration of osseous infection, especially in patients with chronic granulomatous disease or sickle cell disease. (See <a class="local">'Extraintestinal infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Decisions regarding whether to pursue radiographic evaluation should be guided by clinical circumstances and physical examination findings. We have a lower threshold for radiographic imaging in patients &gt;50 years of age, patients with recurrent or prolonged bacteremia, patients with underlying immune compromise or known atherosclerotic disease, and patients with implanted prosthetic material (such as a prosthetic heart valve or prosthetic joint).</p><p></p><p class="bulletIndent1">In the setting of suspected endovascular infection, radiographic evaluation should consist of computed tomography (CT) or magnetic resonance imaging (MRI), preferably with contrast angiographic analysis. (See  <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">"Overview of infected (mycotic) arterial aneurysm", section on 'Diagnosis'</a>.) </p><p></p><p class="bulletIndent1">Echocardiography is warranted for patients with prosthetic valves as well as for patients with native valves in the context of underlying valve disease and/or new cardiac murmur. (See  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Cardiac imaging'</a> and  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis", section on 'Cardiac imaging'</a>.)</p><p></p><p class="headingAnchor" id="H4291833142"><span class="h2">Evaluation for underlying comorbidities</span><span class="headingEndMark"> — </span>In patients with "primary bacteremia" (ie, a positive blood culture in the absence of recent or current gastrointestinal symptoms of <em>Salmonella</em> infection), this finding may reflect an underlying immunocompromising condition (such as HIV infection, liver disease, or malignancy). In such cases, further evaluation is warranted, guided by individual clinical circumstances.</p><p class="headingAnchor" id="H9"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Infectious diseases consultation is advisable for management of patients with known or suspected nontyphoidal <em>Salmonella</em> bacteremia. </p><p class="headingAnchor" id="H1611243890"><span class="h2">Bacteremia</span></p><p class="headingAnchor" id="H911119813"><span class="h3">Initial antibiotic therapy</span></p><p class="headingAnchor" id="H288564452"><span class="h4">Indications</span><span class="headingEndMark"> — </span>Initial antibiotic therapy is warranted for patients with nontyphoidal <em>Salmonella</em> bacteremia pending susceptibility results. (See <a class="local">'Clinical suspicion'</a> above.) </p><p>In such cases, prompt initiation of antibiotic therapy is likely of greater clinical importance than the possibility of prolonging fecal carriage. (See  <a class="medical medical_review" href="/z/d/html/2697.html" rel="external">"Nontyphoidal Salmonella: Gastrointestinal infection and asymptomatic carriage", section on 'Asymptomatic carriage'</a>.) </p><p class="headingAnchor" id="H3421738843"><span class="h4">Selection</span><span class="headingEndMark"> — </span>Given the increasing prevalence of antimicrobial resistance, local antibiotic resistance patterns must be taken into account when choosing empiric therapy. Antibiotic therapy should be tailored to susceptibility data once available. (See  <a class="medical medical_review" href="/z/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology", section on 'Antimicrobial resistance'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred agents</strong> – Preferred antibiotic agents for treatment of nontyphoidal <em>Salmonella</em> bacteremia include a third-generation cephalosporin or fluoroquinolone, given the high tissue and intracellular concentrations of these agents. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">For patients with suspected endovascular infection (eg, patients with bacteremia in the setting of a prosthetic heart valve), initial empiric treatment with both a third-generation cephalosporin as well as a fluoroquinolone is reasonable (given the potential morbidity of such infections), pending susceptibility data.</p><p></p><p class="bulletIndent1">The US Food and Drug Administration (FDA) has issued warnings about adverse effects associated with fluoroquinolones [<a href="#rid54">54</a>]; the benefits of fluoroquinolones may outweigh these risks in treatment of <em>Salmonella</em> infections and should be considered carefully. In children, fluoroquinolones are frequently avoided [<a href="#rid55">55</a>]; however, treatment of serious <em>Salmonella</em> infection is a reasonable indication for their use, especially if other agents are not readily available [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative agents</strong> – Alternative agents for treatment of nontyphoidal <em>Salmonella</em> bacteremia include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>. <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> is another possible alternative agent, although microbiology laboratory capabilities for susceptibility testing are varied and evolving; in rare cases, azithromycin may be useful for treatment of select patients with nontyphoidal<em> Salmonella</em> infection. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">For highly resistant organisms, <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> may be used, with expert consultation. </p><p></p><p class="bulletIndent1">Susceptibility testing for first- and second-generation cephalosporins is generally not reported by most laboratories, and these agents are not recommended for treatment of salmonellosis. </p><p></p><p class="headingAnchor" id="H737591178"><span class="h3">Directed antibiotic therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Susceptibility testing</strong> – Once susceptibility data are available, antibiotics should be tailored to the microbiology data and clinical circumstances. </p><p></p><p class="bulletIndent1">For determination of fluoroquinolone susceptibility in cases of invasive salmonellosis, direct testing should be performed [<a href="#rid57">57</a>]. Previously, nalidixic acid disc resistance screening was used as a marker for relative resistance to fluoroquinolones; however, this approach does not detect all mechanisms of fluoroquinolone resistance. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Susceptible isolates</strong> – The options for directed antimicrobial therapy (including preferred and alternative agents) are the same as for empiric therapy  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>). (See <a class="local">'Selection'</a> above.)</p><p></p><p class="bulletIndent2">There are no comparative trials of antimicrobial agents for treatment of nontyphoidal <em>Salmonella</em> bacteremia. The choice of agent should be guided by the clinical presentation, patient age, presence or absence of suppurative foci (and, if present, feasibility of debridement), and adverse drug effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug-resistant isolates</strong> – For treatment of infection due to highly resistant organisms, carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> 1 g intravenously (IV) every eight hours for adults; 20 mg/kg IV every eight hours [maximum 1000 mg/dose] for children) may be used [<a href="#rid58">58,59</a>]; carbapenem resistance has only rarely been noted in case reports [<a href="#rid60">60,61</a>]. In such cases, consultation with an expert in infectious diseases is advised. </p><p></p><p class="headingAnchor" id="H2895373068"><span class="h3">Treatment duration and suppressive therapy</span><span class="headingEndMark"> — </span>For patients with nontyphoidal <em>Salmonella</em> bacteremia in the absence of extraintestinal focal infection, the duration of antimicrobial therapy should be guided by the host immune status. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients</strong> – For otherwise healthy individuals with bacteremia complicating acute gastroenteritis, a 10- to 14-day course of antimicrobial therapy is reasonable. For patients &gt;12 months and &lt;50 years of age with no comorbidities, shorter courses may be acceptable; however, rare cases of focal infection or relapse can occur even in these groups, and clinical studies regarding treatment of salmonellosis are limited to retrospective data [<a href="#rid62">62,63</a>]. Immunocompetent patients who have improved on IV therapy, are not believed to be at high risk for focal infections, have susceptible organisms, and can be followed closely as outpatients may complete treatment with highly bioavailable oral antibiotic therapy (eg, a fluoroquinolone). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients</strong> – For immunocompromised patients  (<a class="graphic graphic_table graphicRef143569" href="/z/d/graphic/143569.html" rel="external">table 1</a>), we treat for four to six weeks, given higher risk of recurrence or relapse [<a href="#rid3">3,64,65</a>]. </p><p></p><p class="bulletIndent1">Following initial treatment, we administer oral suppressive therapy, especially if relapse has already occurred after an initial course of treatment: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The choice of suppressive therapy should be guided by antimicrobial susceptibility data; options include <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg once daily), <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (750 mg once daily), or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tablet once daily). Consultation with infectious disease experts is recommended.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal duration of suppressive therapy is uncertain and should be determined in conjunction with infectious diseases consultation; considerations include patient age, life expectancy, site of infection, consequences of relapse, and adverse drug effects. </p><p></p><p class="headingAnchor" id="H257261303"><span class="h2">Extraintestinal infection</span><span class="headingEndMark"> — </span>Management of extraintestinal nontyphoidal <em>Salmonella </em>infection consists of surgical consultation regarding debridement in conjunction with prolonged antimicrobial therapy. </p><p class="headingAnchor" id="H3697560541"><span class="h3">Surgical debridement</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endovascular infection</strong> – Experienced vascular surgeons should be consulted for management of patients with endovascular nontyphoidal <em>Salmonella </em>infection [<a href="#rid66">66,67</a>]. Medical therapy alone is inadequate; surgery is required. </p><p></p><p class="bulletIndent1">The surgical approach should be determined based on anatomic site, radiographic findings, intraoperative findings, and degree of debridement necessary and possible. Most experts perform in-situ debridement and grafting (despite the risk of leak and relapsed infection) given the morbidity of extra-anatomic bypass. For patients who are too frail to undergo open surgical repair, endovascular aneurysm repair may be a reasonable alternative [<a href="#rid68">68-70</a>]. </p><p></p><p class="bulletIndent1">Infectious and mechanical complications may occur, including relapse [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other forms of extraintestinal infection</strong> – Patients with visceral infection warrant debridement; the approach should be guided by the anatomic site of involvement.</p><p></p><p class="bulletIndent1">For other forms of extraintestinal infection (including endocarditis, musculoskeletal infection, and central nervous system infection), the approach to surgical intervention is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">"Surgery for left-sided native valve infective endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">"Septic arthritis in adults", section on 'Joint drainage'</a> and  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Surgical management'</a> and  <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management", section on 'Indications for surgery'</a> and  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults", section on 'Surgery'</a> and  <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">"Treatment and prognosis of bacterial brain abscess", section on 'Surgery'</a>.)</p><p></p><p class="headingAnchor" id="H2064288933"><span class="h3">Antibiotic therapy</span></p><p class="headingAnchor" id="H1556432285"><span class="h4">Initial management</span><span class="headingEndMark"> — </span>The approach to antibiotic therapy should be guided by the site of infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endovascular infection, endocarditis, musculoskeletal infection, or central nervous system infection</strong> – For patients with involvement of these sites, we administer antimicrobial therapy for at least six to eight weeks following surgical debridement. The approach to antibiotic selection is as discussed above for treatment of bacteremia  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>). (See <a class="local">'Bacteremia'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral infection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunocompetent patients</strong> – For immunocompetent patients with visceral infection who undergo complete surgical debridement in the absence of complications, we administer antimicrobial therapy for at least three weeks postoperatively. The approach to antibiotic selection is the same as discussed above for treatment of bacteremia  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>). (See <a class="local">'Bacteremia'</a> above.)</p><p></p><p class="bulletIndent2">If complete debridement is not feasible, the duration of treatment should be tailored to individual circumstances, guided by follow-up imaging.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunocompromised patients</strong> – For immunocompromised patients (see <a class="local">'Clinical suspicion'</a> above), we administer antimicrobial therapy for at least six to eight weeks, given higher risk of recurrence or relapse [<a href="#rid3">3,64,65</a>]. </p><p></p><p class="headingAnchor" id="H1367415185"><span class="h4">Suppressive therapy</span><span class="headingEndMark"> — </span>For patients with extraintestinal infection in the settings outlined below, we administer oral suppressive therapy following completion of initial antibiotic therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with indwelling hardware or devices (such as vascular grafts, prosthetic heart valves, or orthopedic hardware), given the challenge of eradicating <em>Salmonella</em> infection and the potentially severe consequences of relapsed infection. </p><p></p><p>The choice of suppressive therapy should be guided by antimicrobial susceptibility data, in conjunction with infectious diseases consultation. Options include <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg once daily), <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (750 mg once daily), or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tablet once daily). </p><p>The optimal duration of suppressive therapy is uncertain and should be determined in conjunction with infectious disease consultation; considerations include patient age, life expectancy, site of infection, consequences of relapse, and adverse drug effects. </p><p class="headingAnchor" id="H3762470237"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>The prognosis of nontyphoidal <em>Salmonella</em> bacteremia is highly variable and depends on host immunity as well as the presence or absence of suppurative foci of infection. Acute bacteremia complicating gastroenteritis in immunocompetent patients between 12 months and 50 years of age usually resolves promptly with appropriate antibiotic therapy. Among infants with nontyphoidal <em>Salmonella</em> meningitis, mortality may be ≥50 percent; among adults, complications are rare [<a href="#rid48">48</a>]. </p><p>For patients with endovascular infection, small surgical series of up to 26 patients have demonstrated a 60 to 100 percent survival rate [<a href="#rid18">18,51,67</a>]. In a study in Sweden including 19 patients with infected aortic aneurysm due to nontyphoidal <em>Salmonella</em> infection who underwent vascular surgery, two-year survival was 74 percent (compared with 62 percent patients with <em>S. aureus</em> as the etiologic pathogen) [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H1615404491"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110029.html" rel="external">"Society guideline links: Acute diarrhea in children"</a>.)</p><p class="headingAnchor" id="H15836061"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83760.html" rel="external">"Patient education: Salmonella infection (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Salmonellae are motile gram-negative bacilli that cause a broad range of clinical infection in humans. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Host risk factors</strong> – Patients at increased risk for nontyphoidal <em>Salmonella</em> bacteremia are summarized in the table  (<a class="graphic graphic_table graphicRef143569" href="/z/d/graphic/143569.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transmission</strong> – Nontyphoidal <em>Salmonella</em> are transmitted by the fecal-oral route; this includes transmission within households or between close contacts, outbreaks related to contaminated food and water, and transmission to humans from farm or pet animals. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacteremia</strong> – In adults, the clinical presentation is variable and depends upon the <em>Salmonella</em> serotype as well as the host immune status and underlying comorbidities. In children, bacteremia is associated with gastrointestinal symptoms in 70 to 80 percent of cases. (See <a class="local">'Bacteremia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extraintestinal infection</strong> – The most clinically important forms of extraintestinal infection are endovascular infection and central nervous system infection since definitive debridement of these sites is not feasible in most cases. Other forms include endocarditis, musculoskeletal infection, and visceral infection (involvement of the spleen, liver, heart, lung, or pleura). (See <a class="local">'Extraintestinal infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse</strong> – Among immunocompromised patients, if bacteremia occurs at an immunological nadir, infection may become established within the reticuloendothelial system. Relapse may occur even after an asymptomatic interval and in the absence of a known focus of infection. (See <a class="local">'Relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical suspicion and obtaining cultures</strong> – Nontyphoidal<em> Salmonella </em>bacteremia should be suspected in patients with gastrointestinal symptoms (recent or current) and systemic febrile illness in patients with risk factors  (<a class="graphic graphic_table graphicRef143569" href="/z/d/graphic/143569.html" rel="external">table 1</a>). In such patients, blood cultures should be obtained to establish a microbiologic diagnosis. (See <a class="local">'Clinical suspicion'</a> above and <a class="local">'Obtaining cultures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation for extraintestinal complications</strong> – Patients with nontyphoidal <em>Salmonella</em> bacteremia should have a careful physical examination for possible extraintestinal metastatic foci of infection. Decisions regarding whether to pursue radiographic evaluation should be guided by clinical circumstances. We have a lower threshold for radiographic imaging in patients &gt;50 years of age, patients with recurrent or prolonged bacteremia, patients with underlying immune compromise or known atherosclerotic disease, and patients with implanted prosthetic material (such as a prosthetic heart valve or prosthetic joint). (See <a class="local">'Evaluation for extraintestinal complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial antibiotic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacteremia</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Antibiotic selection</strong> – For patients with nontyphoidal<em> Salmonella </em>bacteremia, we suggest initial treatment with either a third-generation cephalosporin or fluoroquinolone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the high tissue and intracellular concentrations of these agents. </p><p></p><p class="bulletIndent3">For patients with suspected endovascular infection (eg, patients with bacteremia in the setting of a prosthetic heart valve), we suggest initial empiric treatment with both a third-generation cephalosporin as well as a fluoroquinolone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the potential morbidity of such infections.</p><p></p><p class="bulletIndent3">Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>). Antibiotic selection should be guided by local resistance patterns and tailored to susceptibility data when available. (See <a class="local">'Selection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Duration</strong> – For otherwise healthy individuals with bacteremia complicating acute gastroenteritis, a 10- to 14-day course of antimicrobial therapy is reasonable. For immunocompromised patients, we treat for four to six weeks, given higher risk of recurrence or relapse. (See <a class="local">'Treatment duration and suppressive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extraintestinal infection</strong> – Management of extraintestinal nontyphoidal <em>Salmonella </em>infection consists of surgical debridement in conjunction with prolonged antimicrobial therapy. (See <a class="local">'Extraintestinal infection'</a> above.)</p><p></p><p class="bulletIndent2">The approach to antibiotic selection is the same as for treatment of bacteremia  (<a class="graphic graphic_table graphicRef143698" href="/z/d/graphic/143698.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent2">The duration of antibiotic therapy should be guided by the site of infection (see <a class="local">'Initial management'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Endovascular infection, endocarditis, musculoskeletal infection, or central nervous system infection</strong> – For patients with involvement of these sites, we administer antimicrobial therapy for at least six to eight weeks following surgical debridement. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Visceral infection</strong> – For immunocompetent patients with visceral infection who undergo complete surgical debridement in the absence of complications, we administer antimicrobial therapy for at least three weeks postoperatively. </p><p></p><p class="bulletIndent3">For immunocompromised patients, we administer antimicrobial therapy for at least six to eight weeks, given higher risk of recurrence or relapse. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suppressive therapy</strong> – For patients in the following categories, we suggest oral suppressive therapy following completion of initial antibiotic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Suppressive therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromised patients, especially if relapse has already occurred after an initial course of treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with indwelling hardware or devices (such as vascular grafts, prosthetic heart valves, or orthopedic hardware), given the challenge of eradicati<em>ng Salmonella</em> infection and the potentially severe consequences of relapsed infection. </p><p></p><p class="bulletIndent1">The choice of suppressive therapy should be guided by antimicrobial susceptibility data. The duration of suppressive therapy is uncertain; considerations include patient age, life expectancy, site of infection, consequences of relapse, and adverse drug effects. Decisions regarding suppressive therapy should be made conjunction with infectious diseases expertise. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GBD 2017 Non-Typhoidal Salmonella Invasive Disease Collaborators. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19:1312.</a></li><li><a class="nounderline abstract_t">Dhanoa A, Fatt QK. Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression. Ann Clin Microbiol Antimicrob 2009; 8:15.</a></li><li><a class="nounderline abstract_t">Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633.</a></li><li><a class="nounderline abstract_t">Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963.</a></li><li><a class="nounderline abstract_t">Kariuki S, Revathi G, Kariuki N, et al. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006; 6:101.</a></li><li><a class="nounderline abstract_t">Kariuki S, Revathi G, Kariuki N, et al. Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585.</a></li><li><a class="nounderline abstract_t">Sigaúque B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J 2009; 28:108.</a></li><li><a class="nounderline abstract_t">Uche IV, MacLennan CA, Saul A. A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014). PLoS Negl Trop Dis 2017; 11:e0005118.</a></li><li><a class="nounderline abstract_t">Symmons DP, Silman AJ. The world of biologics. Lupus 2006; 15:122.</a></li><li><a class="nounderline abstract_t">Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28:331.</a></li><li><a class="nounderline abstract_t">Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37:304.</a></li><li><a class="nounderline abstract_t">Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413.</a></li><li><a class="nounderline abstract_t">Hung TY, Liu MC, Hsu CF, Lin YC. Rotavirus infection increases the risk of bacteremia in children with nontyphoid Salmonella gastroenteritis. Eur J Clin Microbiol Infect Dis 2009; 28:425.</a></li><li><a class="nounderline abstract_t">Krumkamp R, Kreuels B, Sarpong N, et al. Association Between Malaria and Invasive Nontyphoidal Salmonella Infection in a Hospital Study: Accounting for Berkson's Bias. Clin Infect Dis 2016; 62 Suppl 1:S83.</a></li><li><a class="nounderline abstract_t">Biggs HM, Lester R, Nadjm B, et al. Invasive Salmonella infections in areas of high and low malaria transmission intensity in Tanzania. Clin Infect Dis 2014; 58:638.</a></li><li><a class="nounderline abstract_t">Chau JY, Tiffany CM, Nimishakavi S, et al. Malaria-associated L-arginine deficiency induces mast cell-associated disruption to intestinal barrier defenses against nontyphoidal Salmonella bacteremia. Infect Immun 2013; 81:3515.</a></li><li><a class="nounderline abstract_t">Zaidi E, Bachur R, Harper M. Non-typhi Salmonella bacteremia in children. Pediatr Infect Dis J 1999; 18:1073.</a></li><li><a class="nounderline abstract_t">Shimoni Z, Pitlik S, Leibovici L, et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822.</a></li><li><a class="nounderline abstract_t">Feasey NA, Dougan G, Kingsley RA, et al. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet 2012; 379:2489.</a></li><li><a class="nounderline abstract_t">Mandal BK, Brennand J. Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit. BMJ 1988; 297:1242.</a></li><li><a class="nounderline abstract_t">Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosis outcomes differ substantially by serotype. J Infect Dis 2008; 198:109.</a></li><li><a class="nounderline abstract_t">Greenhow TL, Alabaster A. Epidemiology of Nontyphoidal Salmonella Bloodstream Infections in Children. Pediatrics 2023; 152.</a></li><li><a class="nounderline abstract_t">Krueger AL, Greene SA, Barzilay EJ, et al. Clinical outcomes of nalidixic acid, ceftriaxone, and multidrug-resistant nontyphoidal salmonella infections compared with pansusceptible infections in FoodNet sites, 2006-2008. Foodborne Pathog Dis 2014; 11:335.</a></li><li><a class="nounderline abstract_t">Varma JK, Molbak K, Barrett TJ, et al. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis 2005; 191:554.</a></li><li><a class="nounderline abstract_t">Tsai MH, Huang YC, Chiu CH, et al. Nontyphoidal Salmonella bacteremia in previously healthy children: analysis of 199 episodes. Pediatr Infect Dis J 2007; 26:909.</a></li><li><a class="nounderline abstract_t">Punpanich W, Netsawang S, Thippated C. Invasive salmonellosis in urban Thai children: a ten-year review. Pediatr Infect Dis J 2012; 31:e105.</a></li><li><a class="nounderline abstract_t">Fierer J. Invasive Non-typhoidal Salmonella (iNTS) Infections. Clin Infect Dis 2022; 75:732.</a></li><li><a class="nounderline abstract_t">Rodríguez M, de Diego I, Martínez N, et al. Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991-2001). Int J Med Microbiol 2006; 296:211.</a></li><li><a class="nounderline abstract_t">Ramos JM, Aguado JM, García-Corbeira P, et al. Clinical spectrum of urinary tract infections due on nontyphoidal Salmonella species. Clin Infect Dis 1996; 23:388.</a></li><li><a class="nounderline abstract_t">Hsu RB, Lin FY. Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal. QJM 2005; 98:821.</a></li><li><a class="nounderline abstract_t">Cohen PS, O'Brien TF, Schoenbaum SC, Medeiros AA. The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 1978; 89:931.</a></li><li><a class="nounderline abstract_t">Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001; 110:60.</a></li><li><a class="nounderline abstract_t">Castellon SA, Hinkin CH, Myers HF. Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection. J Int Neuropsychol Soc 2000; 6:336.</a></li><li><a class="nounderline abstract_t">Cheng WL, Li CW, Li MC, et al. Salmonella infective endocarditis. J Microbiol Immunol Infect 2016; 49:313.</a></li><li><a class="nounderline abstract_t">Chen SY, Weng TH, Tseng WP, et al. Value of blood culture time to positivity in identifying complicated nontyphoidal Salmonella bacteremia. Diagn Microbiol Infect Dis 2018; 91:210.</a></li><li><a class="nounderline abstract_t">Lin HW, Hsu HS, Huang YT, et al. Time to positivity in blood cultures of adults with nontyphoidal Salmonella bacteremia. J Microbiol Immunol Infect 2016; 49:417.</a></li><li><a class="nounderline abstract_t">Lin JJ, Weng TH, Tseng WP, et al. Utility of a blood culture time to positivity-incorporated scoring model in predicting vascular infections in adults with nontyphoid Salmonella bacteremia. J Microbiol Immunol Infect 2018; 51:652.</a></li><li><a class="nounderline abstract_t">Winicki NM, Desai D, Desai A, et al. 'From Gut to Heart': A rare case of Salmonella Typhimurium Bacteremia and native valve endocarditis. IDCases 2023; 32:e01787.</a></li><li><a class="nounderline abstract_t">Gorki H, Nicolay NH, Loulmet DF, et al. Non-typhoid Salmonellae and prosthetic valve endocarditis: more than a rare coincidence? A review of the literature. J Heart Valve Dis 2009; 18:401.</a></li><li><a class="nounderline abstract_t">Hegeman EM, Bates T, Lynch T, Schmitz MR. Osteomyelitis in Sickle Cell Anemia: Does Age Predict Risk of Salmonella Infection? Pediatr Infect Dis J 2023; 42:e262.</a></li><li><a class="nounderline abstract_t">Tsagris V, Vliora C, Mihelarakis I, et al. Salmonella Osteomyelitis in Previously Healthy Children: Report of 4 Cases and Review of the Literature. Pediatr Infect Dis J 2016; 35:116.</a></li><li><a class="nounderline abstract_t">Gill AN, Muller ML, Pavlik DF, et al. Nontyphoidal Salmonella Osteomyelitis in Immunocompetent Children Without Hemoglobinopathies: A Case Series and Systematic Review of the Literature. Pediatr Infect Dis J 2017; 36:910.</a></li><li><a class="nounderline abstract_t">Day LJ, Qayyum QJ, Kauffman CA. Salmonella prosthetic joint septic arthritis. Clin Microbiol Infect 2002; 8:427.</a></li><li><a class="nounderline abstract_t">Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr 2013; 31:299.</a></li><li><a class="nounderline abstract_t">Pogreba-Brown K, Austhof E, Tang X, et al. Enteric Pathogens and Reactive Arthritis: Systematic Review and Meta-Analyses of Pathogen-Associated Reactive Arthritis. Foodborne Pathog Dis 2021; 18:627.</a></li><li><a class="nounderline abstract_t">Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal infants in Thailand. Pediatr Infect Dis J 2001; 20:581.</a></li><li><a class="nounderline abstract_t">Molyneux EM, Mankhambo LA, Phiri A, et al. The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006. Ann Trop Paediatr 2009; 29:13.</a></li><li><a class="nounderline abstract_t">Cohen JI, Bartlett JA, Corey GR. Extra-intestinal manifestations of salmonella infections. Medicine (Baltimore) 1987; 66:349.</a></li><li><a class="nounderline abstract_t">Keddy KH, Sooka A, Musekiwa A, et al. Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013. Clin Infect Dis 2015; 61 Suppl 4:S272.</a></li><li><a class="nounderline abstract_t">Ting SMV, Ding CH, Wahab AA. Brain abscess caused by Salmonella Enteritidis following craniotomy for meningioma: A case report and literature review. Malays J Pathol 2021; 43:333.</a></li><li><a class="nounderline abstract_t">Chen PL, Chang CM, Wu CJ, et al. Extraintestinal focal infections in adults with nontyphoid Salmonella bacteraemia: predisposing factors and clinical outcome. J Intern Med 2007; 261:91.</a></li><li><a class="nounderline abstract_t">Mori N, Szvalb AD, Adachi JA, et al. Clinical presentation and outcomes of non-typhoidal Salmonella infections in patients with cancer. BMC Infect Dis 2021; 21:1021.</a></li><li><a class="nounderline abstract_t">Hess LM, Burdick B, Minard CG, Dutta A. IV Antibiotic Durations for Nontyphoidal Salmonella Bacteremia. Hosp Pediatr 2019; 9:993.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics (Accessed on January 09, 2020).</li><li><a class="nounderline abstract_t">Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.</a></li><li><a class="nounderline abstract_t">Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18:64.</a></li><li><a class="nounderline abstract_t">Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.</a></li><li><a class="nounderline abstract_t">Jean SS, Lee YT, Guo SM, Hsueh PR. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem. J Infect 2005; 51:e163.</a></li><li><a class="nounderline abstract_t">Li WC, Huang FY, Liu CP, et al. Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases. J Clin Microbiol 2005; 43:3237.</a></li><li><a class="nounderline abstract_t">Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.</a></li><li><a class="nounderline abstract_t">Day MR, Meunier D, Doumith M, et al. Carbapenemase-producing Salmonella enterica isolates in the UK. J Antimicrob Chemother 2015; 70:2165.</a></li><li><a class="nounderline abstract_t">Wen SC, Best E, Nourse C. Non-typhoidal Salmonella infections in children: Review of literature and recommendations for management. J Paediatr Child Health 2017; 53:936.</a></li><li><a class="nounderline abstract_t">Neumann S, Malik SS, Marcus-Samuels B, et al. Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and Gi/o Proteins. Mol Pharmacol 2020; 97:2.</a></li><li><a class="nounderline abstract_t">Hsu RB, Lin FY. Nontyphoid Salmonella infection in heart transplant recipients. Am J Med Sci 2008; 336:393.</a></li><li><a class="nounderline abstract_t">Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78:235.</a></li><li><a class="nounderline abstract_t">Oskoui R, Davis WA, Gomes MN. Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature. Arch Intern Med 1993; 153:517.</a></li><li><a class="nounderline abstract_t">Lee CH, Hsieh HC, Ko PJ, et al. Treatment of infected abdominal aortic aneurysm caused by Salmonella. Ann Vasc Surg 2014; 28:217.</a></li><li><a class="nounderline abstract_t">Sörelius K, Budtz-Lilly J, Mani K, Wanhainen A. Systematic Review of the Management of Mycotic Aortic Aneurysms. Eur J Vasc Endovasc Surg 2019; 58:426.</a></li><li><a class="nounderline abstract_t">Luo CM, Chan CY, Chen YS, et al. Long-term Outcome of Endovascular Treatment for Mycotic Aortic Aneurysm. Eur J Vasc Endovasc Surg 2017; 54:464.</a></li><li><a class="nounderline abstract_t">Guo Y, Bai Y, Yang C, et al. Mycotic aneurysm due to Salmonella species: clinical experiences and review of the literature. Braz J Med Biol Res 2018; 51:e6864.</a></li><li><a class="nounderline abstract_t">Sörelius K, Wanhainen A, Furebring M, et al. The Microbiology of Infective Native Aortic Aneurysms in a Population-Based Setting. Ann Vasc Surg 2022; 78:112.</a></li></ol></div><div id="topicVersionRevision">Topic 3126 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445730" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12172085" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173674" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585646" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131902" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Community-acquired bacteremia among children admitted to a rural hospital in Mozambique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056035" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634363" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The world of biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797940" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804667" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Septic arthritis due to Salmonella enteritidis associated with infliximab use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474400" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Salmonella infections in immunocompromised adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18949496" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rotavirus infection increases the risk of bacteremia in children with nontyphoid Salmonella gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933027" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association Between Malaria and Invasive Nontyphoidal Salmonella Infection in a Hospital Study: Accounting for Berkson's Bias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336909" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Invasive Salmonella infections in areas of high and low malaria transmission intensity in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690397" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Malaria-associated L-arginine deficiency induces mast cell-associated disruption to intestinal barrier defenses against nontyphoidal Salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608627" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Non-typhi Salmonella bacteremia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825045" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22587967" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3145067" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462137" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Salmonellosis outcomes differ substantially by serotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37671462" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemiology of Nontyphoidal Salmonella Bloodstream Infections in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24617446" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical outcomes of nalidixic acid, ceftriaxone, and multidrug-resistant nontyphoidal salmonella infections compared with pansusceptible infections in FoodNet sites, 2006-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15655779" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901796" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nontyphoidal Salmonella bacteremia in previously healthy children: analysis of 199 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22531240" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Invasive salmonellosis in urban Thai children: a ten-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35041743" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Invasive Non-typhoidal Salmonella (iNTS) Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621698" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991-2001).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842280" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical spectrum of urinary tract infections due on nontyphoidal Salmonella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16203825" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/717990" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The risk of endothelial infection in adults with salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152867" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824505" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25882489" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Salmonella infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526450" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Value of blood culture time to positivity in identifying complicated nontyphoidal Salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311404" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Time to positivity in blood cultures of adults with nontyphoidal Salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29501434" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Utility of a blood culture time to positivity-incorporated scoring model in predicting vascular infections in adults with nontyphoid Salmonella bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37214186" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 'From Gut to Heart': A rare case of Salmonella Typhimurium Bacteremia and native valve endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19852144" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Non-typhoid Salmonellae and prosthetic valve endocarditis: more than a rare coincidence? A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37079601" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Osteomyelitis in Sickle Cell Anemia: Does Age Predict Risk of Salmonella Infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418243" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Salmonella Osteomyelitis in Previously Healthy Children: Report of 4 Cases and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28134744" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nontyphoidal Salmonella Osteomyelitis in Immunocompetent Children Without Hemoglobinopathies: A Case Series and Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199853" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Salmonella prosthetic joint septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24288942" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255548" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Enteric Pathogens and Reactive Arthritis: Systematic Review and Meta-Analyses of Pathogen-Associated Reactive Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419499" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systemic nontyphoidal Salmonella infection in normal infants in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222929" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306260" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Extra-intestinal manifestations of salmonella infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449942" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448798" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Brain abscess caused by Salmonella Enteritidis following craniotomy for meningioma: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222172" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Extraintestinal focal infections in adults with nontyphoid Salmonella bacteraemia: predisposing factors and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587893" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical presentation and outcomes of non-typhoidal Salmonella infections in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31704707" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : IV Antibiotic Durations for Nontyphoidal Salmonella Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31704707" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : IV Antibiotic Durations for Nontyphoidal Salmonella Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402381" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Quinolone arthropathy in animals versus children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470165" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of fluoroquinolones in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752519" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230198" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000441" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654661" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795771" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Carbapenemase-producing Salmonella enterica isolates in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556448" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Non-typhoidal Salmonella infections in children: Review of literature and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31704717" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and Gi/o Proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011395" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nontyphoid Salmonella infection in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2047518" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435031" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084275" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of infected abdominal aortic aneurysm caused by Salmonella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31320247" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Systematic Review of the Management of Mycotic Aortic Aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826996" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term Outcome of Endovascular Treatment for Mycotic Aortic Aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29947649" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycotic aneurysm due to Salmonella species: clinical experiences and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34537347" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The Microbiology of Infective Native Aortic Aneurysms in a Population-Based Setting.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
